Piretanide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO HTN 6-12 mg/day. Oedema associated w/ heart failure 3-6 mg/day.
Dosage Details
Oral
Hypertension
Adult: 6-12 mg daily.

Oral
Oedema associated with heart failure
Adult: 3-6 mg daily.
Contraindications
Severe hepatic or renal impairment; anuria; Addison's disease; hypercalcaemia.
Special Precautions
Fluid and electrolyte disturbances; hepatic cirrhosis; gout; diabetes mellitus. Elderly; severe heart failure; renal or hepatic impairment. Monitor blood glucose concentrations in patients taking antidiabetics. Monitor for signs of fluid and electrolyte imbalance. May exacerbate or unmask SLE. Pregnancy and lactation.
Adverse Reactions
Hyponatraemia, hypokalaemia, hypomagnesaemia, hypochloraemic alkalosis, increased Ca excretion, hypotension; nausea, GI disturbances, hyperuricaemia, gout; hyperglycaemia; temporary increase in plasma cholesterol and TG concentrations; rarely, rashes, photosensitivity, bone marrow depression (withdraw treatment), pancreatitis (with large parenteral doses), tinnitus and deafness (usually with large parenteral doses and rapid admin and in renal impairment); muscle cramps (high doses).
Drug Interactions
May increase the nephrotoxicity of cephalosporins and ototoxicity of aminoglycosides and other ototoxic drugs. Severe electrolyte disturbances may occur when used with metolazone. May increase the plasma concentrations of lithium. NSAIDs may reduce the efficacy of piretanide. Decreased natriuretic effect when used with probenecid.
Action
Description: Piretanide inhibits the reabsorption of electrolytes primarily in the thick ascending limb of the loop of Henle and also in the distal renal tubules. It may also have a direct effect in the proximal tubules. Excretion of sodium, potassium, Ca and chloride ions is increased and water excretion enhanced.
Pharmacokinetics:
Absorption: Almost completely absorbed after oral doses.
Distribution: Extensively bound to plasma proteins.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Piretanide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in